Clinical Trials Logo

Gastrointestinal Carcinoid Tumor clinical trials

View clinical trials related to Gastrointestinal Carcinoid Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT00730483 Active, not recruiting - Metastatic Cancer Clinical Trials

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Start date: February 2009
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.

NCT ID: NCT00454376 Active, not recruiting - Lung Cancer Clinical Trials

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

Start date: October 2006
Phase: Phase 4
Study type: Observational

RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors. PURPOSE: This phase IV clinical trial is studying how well a disease-specific questionnaire works in assessing the quality of life of patients with gastrointestinal-related neuroendocrine tumors.

NCT ID: NCT00436735 Active, not recruiting - Colorectal Cancer Clinical Trials

Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors.